Island takes Galidesivir from regulatory planning to Uganda and Marburg execution

Uganda approvals create a route to prospective human data

Island Pharmaceuticals Limited (ASX:ILA) has cleared the regulatory and ethics approvals needed to make Galidesivir available to patients in Uganda’s ongoing Bundibugyo Ebola outbreak. The treatment would be supplied under the World Health Organization’s Monitored Emergency Use of Unregistered and Investigational Interventions framework, or MEURI, rather than as an approved commercial therapy.

The program is being undertaken with the Uganda Ministry of Health, the ACCEPT-Africa Consortium and Makerere University’s Infectious Diseases Institute. Island says the initiative is sponsored and funded by participating governments and institutions, giving it an opportunity to collect prospective human safety, clinical and virological data without carrying the full cost of a conventional trial. The quality and scope of any resulting data will depend on the number of patients treated and the circumstances of an emergency-use program.

Bundibugyo Ebola has no approved specific treatment, according to the company. Island’s earlier Ebola development work includes a non-human-primate study in which Galidesivir-treated animals recorded 100% survival against Ebola Zaire, compared with no survival among placebo-treated animals. That result is from a different virus and animal setting, so it does not establish efficacy in Bundibugyo patients.

Two Marburg studies now target different treatment windows

Island is also building a larger evidence package for Marburg virus disease under the US Food and Drug Administration’s Animal Rule. Its Texas Biomed dose study will assess Galidesivir in 12 non-human primates infected with the FDA-preferred Angola strain, with treatment beginning after clinical signs typically emerge three to five days after exposure.

That work is designed to complement a planned 20-animal USAMRIID study, where treatment will begin 24 or 48 hours after infection. Taken together, the programs cover 32 animals and are intended to generate efficacy, pharmacokinetic, dose-response and treatment-timing data for dose selection and the design of a planned pivotal efficacy study. Texas Biomed preparation is scheduled for the current quarter, with infection and treatment targeted for early 2027; USAMRIID dosing is expected in the December quarter.

After quarter end, 22 animals completed screening and preparation for the USAMRIID study, including acclimatisation to jackets and tethering systems required for procedures and pharmacokinetic sampling. Twenty animals are required, with two held as reserves. The primary endpoint is survival 28 days after exposure, while viral load, clinical signs and pharmacokinetics will also be assessed.

Manufacturing expands as the program approaches execution

Island has commissioned a second GMP manufacturing campaign with PI Health Sciences and expects to have about 700 to 800 treatment courses available during the December quarter. Physical manufacture of Galidesivir API began on 1 October, with a first 5kg batch targeted for completion by the end of October and a second 5kg batch targeted for November. The first batch is earmarked for the Uganda program, subject to finishing, vialling, packaging and shipment.

The manufacturing push builds on the company’s earlier GMP production campaign and is intended to support the Uganda emergency-use program, the Marburg studies and potential future biodefence procurement. Supply is strategically useful, but it also brings forward spending before the filing reports product revenue or a commercial order.

Regulatory access removes one Animal Rule information hurdle

Island also secured a Letter of Authorisation allowing it to cross-reference a detailed Marburg-Angola non-human-primate natural history study in future FDA submissions. The company says the FDA had identified the lack of sufficiently detailed published information on its proposed model as an issue; the newly obtained access addresses that requirement without Island having to independently repeat an equivalent natural history study.

The milestone complements the Marburg natural history access previously disclosed by Island and gives the upcoming dose optimisation work a regulatory dataset describing untreated disease progression. It strengthens the proposed Animal Rule package, but does not amount to FDA approval or guarantee that a future pivotal study or submission will succeed.

Cash runway is the immediate shareholder constraint

Island ended September with A$7.83 million in cash and cash equivalents, down from A$12.87 million at June quarter-end. Net operating cash outflow was A$4.93 million, driven largely by research and development, non-human-primate work, BSL-4 facility costs, regulatory activity in Africa and GMP manufacturing. On the company’s own calculation, that left an estimated 1.6 quarters of funding and no drawn finance facilities.

Island expects up to A$1.36 million from the exercise of in-the-money options expiring on 4 December, while separately saying about A$3.2 million of vested options were in the money at the announcement date. It is also considering capital management and corporate plans. Management says it is confident of funding ongoing operations, but the report itself expects elevated research spending until the animal studies are complete. The next test is therefore not simply whether the science advances, but whether it can do so without a funding interruption as manufacturing and BSL-4 work continue.